Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
You may also be interested in...
Zika Vaccines Might Be Approved By 2020
Nothing's even in Phase II yet, but sponsors and US government researchers remain optimistic.
Takeda In Hot Pursuit Of Zika Vaccine With $312m US Contract
Takeda is officially in the ballgame, joining the ranks of other firms like Sanofi Pasteur and GlaxoSmithKline, to find a vaccine against the Zika virus after snagging a US government R&D contract worth up to $312m.
Playing the Long Game, Partnerships Required For Emerging Infectious Diseases
Bringing drugs and vaccines for emerging infectious diseases to the marketplace requires playing the long game and collaborations if efforts are going to be successful.